Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

Treatment for a rash on or inside the buttocks may include a combination of creams, self-care, or antivirals. Find a list of ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

When childhood atopic dermatitis persists into adulthood, the large reduction in quality of life suggests that the price of ...

As part of the agreement to divest Caring Brands, Safety Shot will receive three million shares of Caring Brands stock. To ...

Union Therapeutics is looking to advance its PDE4 inhibitor, orismilast, into a Phase III clinical trial for atopic ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon's entry into the $9.58 billion global market for alopecia areata treatment. This ...

Findings from the JADE trials show that abrocitinib at 100 mg and 200 mg was well-tolerated among patients with moderate to severe atopic dermatitis. Abrocitinib has a manageable long-term safety ...